APPENDIX J: <strong>UW</strong>HC <strong>Guidelines</strong> For the <strong>Use</strong> of Beta-Lactam Antibiotics in Patients withReported Allergies to PenicillinPlease address questions, comments, and suggestions regarding this guideline toLee Vermeulen, MS, RPh, FCCP, Director, Center for Drug Policy at 608/262-7537.<strong>Guidelines</strong> developed by <strong>UW</strong>HC Center for Drug PolicyAuthor: Jeffrey Fish, PharmDReviewed by: Infectious Disease Section and Allergy Section, <strong>UW</strong> Hospital and ClinicsCoordination: Lee Vermeulen, MS, RPh, FCCP, Director, CDPApproved by P&T: May 2004Last Review Date: May 2009Next Scheduled Update: May 2011A. Principles and BackgroundThe reported penicillin allergy rate for inpatients and outpatients is 10%. 1-5 Of these patients, 80-90% will not have positive penicillin skin testing, which test for IgE-mediated reactions only. 6,7The patient may state they are allergic to a medication, but the reaction could be an adverse drugreaction (i.e. GI intolerance) or attributed to the disease being treated (i.e., rash caused by viralinfection while on amoxicillin). 6 The positive penicillin skin test also decreases 10% annually aftera penicillin allergic reaction and 78% of penicillin allergic patients have negative skin tests after10 years of avoidance. 8The different types of allergic drug reactions are classified as follows by the Gell and Coombsclassification. 2-4,6,7,9-111.0 Type 1: IgE-mediated1.1 Immediate reactions (onset
4.0 Type 4: Cellular immune-mediated/delayed hypersensitivity reaction4.1 Contact dermatitis4.1.1 Example: health care workers involved in the manufacturing anddispensing of offending agents4.2 Delayed nonurticarial rashes caused by aminopenicillins5.0 Unknown mechanism: erythema multiforme, Stevens-Johnson syndrome, toxic epidermalnecrolysis, fixed drug reaction, pulmonary infiltrates (nitrofurantoin), autoimmune disease(vasculitis, lupus), drug fever, drug-induced hypersensitivity syndrome (antiepileptics)5.1 Penicillin skin testing will not detect these type of reactions5.2 Desensitization should not be performed due to the risk of reactivate of thereactionSwitching to another class of antibiotics due to a reported patient allergy may adversely affectpatient care due to the different antibiotic: 6,12,13• Being less effective• Having more adverse effects• Being more broad-spectrum, leading to increased resistance• Being more expensiveSince beta-lactam antibiotics share a common beta ring, there is a risk of cross-reactivity. 1-20 Anexplanation for not having higher cross-reactivity is that the alpha rings between the differentclasses vary. Penicillins have a thiazolidine ring, cephalosporins have a dihydrothiazine ring,carbapenems have a modified thiazolidine ring and monobactams are missing the alpha ring. 3-5,11 , Some of the antibiotics share common side chains (see section D) which also may contributeto cross-reactivity. 4,7,14,15 This degree of cross-reactivity appears to be greater amongst the sameclass of antibiotics than between classes. 14 The greatest risk of cross-reactivity is amongstpenicillins. 14-16Prior to 1980, the cross-reactivity between penicillins and cephalosporins was reported to be 10-20%. This was probably due to the fact that the cephalosporins used at the time, cephalothin andcephaloridine, share a similar side chain with benzyl penicillin. 7 Also during this time, somecephalosporins were contaminated with trace amounts of penicillin. 7 Since 1980, reaction ratesin penicillin history-positive and skin test-positive patients who received cephalosporinsdecreased to between 1.1 and 4.4%. 3,7,15,16 A review of cross-reactivity and postmarketingstudies of second- and third-generation cephalosporins revealed no increase in allergic reactionsin those patients with a history of penicillin allergy. 8 If a patient is penicillin history-positive, butskin test-negative, they are at no increased risk of cephalosporin cross-reactivity. 5,16 If patientswith a history of penicillin allergies aren’t skin tested, the risk of a reaction when given a secondor third generation cephalosporin is about 1%, but most of these reactions are anaphylaxis. 7The estimated cross-reactivity between carbapenems and other beta-lactams varies dependingon the type of study. Retrospective studies show a cross-reactivity rate of about 9-11%. 5,17-<strong>21</strong>Issues with these retrospective studies were they didn’t verify the penicillin allergies with skintesting, they didn’t limit the definition for allergic reactions to IgE mediated reactions, and theybased their results on chart documentation. <strong>21</strong> Prospective studies had a cross-reactivity rate of0.9-47.4%. <strong>21</strong> The study showing a 47.4% cross-reactivity rate was a positive skin test toimipenem or its metabolites performed in nineteen penicillin skin-test positive patients. None ofthe patients received systemic imipenem. <strong>21</strong> Three other prospective studies showed crossreactivityrates of 0.9-1%. These studies included penicillin skin-test positive patients whoreceived a carbapenem skin test, but not any carbapenem metabolites. Patients who werecarbapenem skin test negative then received a systemic carbapenem via a graded challenge.None of the the patients had an allergic reaction to the systemic carbapenem. <strong>21</strong> Cross-reactivity
- Page 2 and 3:
PREFACEThe Antimicrobial Use Guidel
- Page 4 and 5:
Antimicrobial Cost Table (Cost info
- Page 6 and 7:
Summary of Antibiotic Order Form: S
- Page 8:
LUNGS/PULMONARYCommunity-Acquired P
- Page 12 and 13:
PART I: BY DRUGABACAVIRFor up-to-da
- Page 14 and 15:
constructed systemic-pulmonary shun
- Page 16 and 17:
AMPICILLIN/SULBACTAM (Unasyn ® )Us
- Page 18 and 19:
ATOVAQUONE/PROGUANIL (Malarone ® )
- Page 20 and 21:
CEFAZOLINUsual DoseAdult: Moderate/
- Page 22 and 23:
CommentsDose adjustment required fo
- Page 24 and 25:
1. Typhoid fever. (NOTE: Third-gene
- Page 26 and 27:
-Dutasteride-Eltrombopag-Theophylli
- Page 28 and 29:
CLINDAMYCINUsual DoseAdult: 600-900
- Page 30 and 31:
DAPTOMYCINInfectious Disease approv
- Page 32 and 33:
Concurrent administration with peni
- Page 34 and 35:
• Cisapride (contraindicated) •
- Page 36 and 37:
• Oral contraceptives/hormones -
- Page 38 and 39:
Synergy in infective endocarditis a
- Page 40 and 41:
• Colchicine • Indinavir • Ta
- Page 42 and 43:
• Donepezil • Pioglitazone• D
- Page 44 and 45:
with linezolid should be considered
- Page 46 and 47:
4. Life-threatening Gram-negative i
- Page 48 and 49:
MOXIFLOXACINLevofloxacin and moxifl
- Page 50 and 51:
Indications1. Uncomplicated cystiti
- Page 52 and 53:
CommentsDose adjustment required fo
- Page 54 and 55:
PIPERACILLIN/TAZOBACTAM (Zosyn ® )
- Page 56 and 57:
PRIMAQUINEUsual DoseAdult: Malaria
- Page 58 and 59:
RIFABUTINUsual DoseAdult (150 mg ca
- Page 60 and 61: • Chloramphenicol • Leflunomide
- Page 62 and 63: SULFISOXAZOLENo longer available as
- Page 64 and 65: TICARCILLIN/CLAVULANATE (Timentin
- Page 66 and 67: 2. Recurrent urinary tract infectio
- Page 68 and 69: VANCOMYCINUsual DoseAdult: 1 g Q12H
- Page 70 and 71: Careful monitoring of patients usin
- Page 72 and 73: APPENDIX B: UWHC SURGICAL ANTIMICRO
- Page 74 and 75: GI:Appendectomy 3Anaerobic organism
- Page 76 and 77: VascularLIKELYPATHOGENS• ANTIMICR
- Page 78 and 79: Cleanorthopedicprocedures(other)Sta
- Page 80 and 81: APPENDIX C: THERAPY FOR TUBERCULOSI
- Page 82 and 83: p-Aminosalicylic acid(PAS)Granules
- Page 84 and 85: Appendix D: UNIVERSITY OF WISCONSIN
- Page 86 and 87: Appendix E: UWHC Guidelines for the
- Page 88 and 89: B. Antifungal Prophylaxis for BMT a
- Page 90 and 91: D. Cost ComparisonDrugAmphotericin
- Page 92 and 93: 17. Maertens J, Glasmacher A, Herbr
- Page 94 and 95: 47. Courtney R, Wexler D, Radwanski
- Page 96 and 97: 2.1.7 Patient is without placement
- Page 98 and 99: Medications Approved for Parenteral
- Page 100 and 101: APPENDIX G: Serum Drug Concentratio
- Page 102 and 103: APPENDIX H: Guidelines for Monitori
- Page 104 and 105: 1. Patients with large volumes of d
- Page 106 and 107: 16. Tsuji B, Rybak MJ. The influenc
- Page 108 and 109: APPENDIX I: Infectious Diseases App
- Page 112 and 113: with aztreonam and other beta-lacta
- Page 114 and 115: D. Side Chains1.2.5. The prescriber
- Page 116 and 117: 14. Pichichiro ME. Use of selected
- Page 118 and 119: Appendix KUWHC Guidelines for Cost-
- Page 120 and 121: sulfa and can be prescribed topatie
- Page 122 and 123: superinfection: amoxicillin 1 g PO
- Page 124 and 125: 17. Smucny J, Fahey T, Becker L, Gl
- Page 126 and 127: Appendix M: Guidelines for the Prop
- Page 128 and 129: D. CategorizationPatients should be
- Page 130 and 131: Empiric coverage for Enterococcus i
- Page 132 and 133: H. Necrotizing PancreatitisThe publ
- Page 134 and 135: Bone or JointEndocarditis 4Streptoc
- Page 136 and 137: Candidemia or candidiasis 11Non-neu
- Page 138 and 139: 11. Pappas PG, Kauffman CA, Andes D
- Page 140 and 141: piperacillin/tazobactam. There were
- Page 142 and 143: D. Dose of Antibiotic1. Piperacilli
- Page 144 and 145: TNAVasopressinVoriconazoleMeropenem
- Page 146 and 147: pretreatment with an H1-histamine b
- Page 148 and 149: formal consult is not required, but
- Page 150: K. References1.0 Bliziotis IA, Ples